Date: 2016-03-29
Type of information: Collaboration agreement
Compound: gene transduction technology
Company: Plasticell (UK) Sphere Fluidics (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: • On March 29, 2016, Plasticell, a biotechnology company using combinatorial cell culture technologies for optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with Sphere Fluidics, a company specializing in single cell encapsulation and screening. Plasticell has used its proprietary Combinatorial Cell Culture™ (CombiCult®) platform to develop inexpensive, high-efficiency gene transduction protocols as alternatives to costly commercial transfection reagents currently used in gene therapy trials. Sphere Fluidics has developed high throughput single cell manipulation and screening technology in picoliter volumes. The two partners aim to combine their technologies to develop quantitatively accurate gene transduction systems with improved efficiency, safety and cost savings.
Financial terms:
Latest news:
